Sentien completes venture financing

On April 4, cell therapy company Sentien Biotechnologies Inc. (Cambridge, Mass.) raised $12 million in a series A round co-led by Boehringer Ingelheim Venture Fund and BioInnovation Capital. Chiesi V...